Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 22, 2022 16:02 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha...
The GetSkinHelp WalkING Clinic will be travelling through the streets of Downtown Toronto and help people get the medical attention they need and are waiting for
November 14, 2022 07:07 ET
|
Skinopathy
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Skinopathy, the company behind GetSkinHelp, are helping people avoid months of waiting thanks to The GetSkinHelp WalkING Clinic which will bring the doctor...
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
October 12, 2022 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
$11+ Billion Dermatology Devices Market Size to Grow at 11.2% CAGR, Globally, by 2028 - Growing Prevalence of Skin Cancers and Skin Disorders
September 30, 2022 08:00 ET
|
The Insight Partners
New York, Sept. 30, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology Devices Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast...
Global Immune Checkpoint Inhibitors Market to Surpass US$ 3,902.9 Million by 2030, Says Coherent Market Insights (CMI)
August 29, 2022 08:40 ET
|
CMI
Seattle, Aug. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market is estimated to be valued at US$ 1,444.7 million in 2022 and is...
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
Prostate Cancer Nuclear Medicine Diagnostics Market to Hit $1,315.66 million by 2028 at 10.6% CAGR - Says, The Insight Partners
July 25, 2022 10:30 ET
|
The Insight Partners
New York, July 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global...
Immunocore Announces $140 Million Private Placement Financing
July 18, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...
Monoclonal Antibodies for Oncology Global Market Report 2022
July 08, 2022 05:43 ET
|
Research and Markets
Dublin, July 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed...